Tunlametinib
Tunlametinib is a highly selective, orally bioavailable small molecule inhibitor of MEK1 and MEK2 kinases with a reported IC50 value of 1.9 nM for MEK1. Tunlametinib exerts its antitumor effects by blocking the oncogenic RAS-RAF-MEK-ERK signaling pathway, thereby inducing tumor cell cycle arrest and promoting apoptosis, Tunlametinib demonstrates strong inhibitory activity against various RAS/RAF-mutant cancer cells such as those harboring BRAF V600E or KRAS G12C mutations, shows synergistic effects in combination with BRAF/KRASG12C/SHP2 inhibitors and Docetaxel, and is used in targeted therapy for RAS/RAF-driven cancers including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC) .
Product Specifications
CAS Number
1801756-06-8
Product Name Alternative
HL085, HL-085, Tunlametinib
Field of Research
Signal Transduction
Purity
98.72% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween-80+45% Saline:5 mg/mL (10.18 mM) ; DMSO:80 mg/mL (162.85 mM)
Smiles
O=C (NOCCO) C1=CC=2SC=NC2C (F) =C1NC3=CC=C (I) C=C3F
Molecular Formula
C16H12F2IN3O3S
Molecular Weight
491.25
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SWAP70 (Switch-Associated Protein 70, HSPC321, SWAP-70, FLJ39540, KIAA0640) discontinued
SWAP70 (Switch-Associated Protein 70, HSPC321, SWAP-70, FLJ39540, KIAA0640) discontinued
Mouse Monoclonal Siglec-1/CD169 Antibody (HSn 7D2)
